Glucophage


Also found in: Dictionary, Thesaurus, Wikipedia.
Related to Glucophage: Glucophage xr

metformin hydrochloride

Apo-Metformin (CA), Co Metformin (CA), Dom-Metformin (CA), Fortamet, Gen-Metformin (CA), Glucophage, Glucophage XR, Glumetza, Glycon (CA), Med Metformin (CA), Metsol (UK), Novo-Metformin (CA), Nu-Metformin (CA), PHL-Metformin (CA), PMS-Metformin (CA), Ran-Metformin (CA), Ratio-Metformin (CA), Rhoxal-Metformin (CA), Riomet, Riva-Metformin (CA), Sandoz Metformin (CA)

Pharmacologic class: Biguanide

Therapeutic class: Hypoglycemic

Pregnancy risk category B

FDA Box Warning

• Lactic acidosis is rare but serious (50% mortality) metabolic complication that can result from drug accumulation. Lactic acidosis is also linked to such conditions as diabetes mellitus and significant tissue hypoperfusion and hypoxemia. Lactic acidosis incidence in patients receiving drug is low; cases have occurred mainly in diabetics with significant renal insufficiency. Patients with unstable or acute heart failure at risk of hypoperfusion and hypoxemia are at increased lactic acidosis risk.

• Lactic acidosis risk rises with age and degree of renal dysfunction, and may decrease significantly through regular renal monitoring and by using lowest effective dosage. Perform careful renal monitoring, especially in elderly patients. Withhold drug promptly if patient develops condition linked to hypoxemia, dehydration, or sepsis. Avoid giving drug to patients with hepatic disease, as hepatic impairment may significantly limit lactate clearance. Caution patient against excessive alcohol use during therapy, as alcohol potentiates drug effects on lactate metabolism. Temporarily withdraw drug before intravascular radio-contrast study or surgical procedure.

• Lactic acidosis onset commonly is subtle and accompanied only by nonspecific symptoms. Instruct patient to notify physician immediately if symptoms occur; withdraw drug until situation is clarified.

• Suspect lactic acidosis in diabetic patient with metabolic acidosis who lacks evidence of ketoacidosis.

• Lactic acidosis requires emergency treatment. Discontinue metformin immediately and begin general supportive measures promptly. Prompt hemodialysis is recommended to correct acidosis and remove accumulated drug, and can lead to prompt symptom reversal and recovery.

Action

Increases insulin sensitivity by decreasing glucose production and absorption in liver and intestines and enhancing glucose uptake and utilization

Availability

Oral solution: 100 mg/ml, 500 mg/5 ml

Tablets: 500 mg, 850 mg, 1,000 mg

Tablets (extended-release): 500 mg, 750 mg

Indications and dosages

Adjunct to diet and exercise to improve glycemic control in type 2 (non-insulin-dependent) diabetes mellitus

Adults and children ages 17 and older: Initially, 500 mg P.O. b.i.d.; may increase by 500 mg/week, up to 2,000 mg/day. If patient needs more than 2,000 mg/day, give in three divided doses (not to exceed 2,500 mg/day). Alternatively, 850 mg P.O. daily, increased by 850 mg q 2 weeks, up to 2,550 mg/day in divided doses (850 mg t.i.d.). Extended-release tablets-500 mg/day P.O. with evening meal; may increase by 500 mg weekly, up to 2,000 mg/day. If 2,000 mg once daily is inadequate, 1,000 mg may be given b.i.d.

Children ages 10 to 16: 500 mg P.O. b.i.d. Increase in increments of 500 mg weekly to a maximum of 2,000 mg daily in divided doses.

Concurrent use with sulfonylurea or insulin in type 2 diabetes mellitus

Adults and children ages 17 and older: If patient hasn't responded to maximum metformin dosage of 2,000 mg/day in 4 weeks, sulfonylurea may be added while metformin therapy continues at highest dosage (even if patient experienced primary or secondary failure on sulfonylurea). Adjust dosages of both drugs until glycemic control adequate. If response inadequate within 1 to 3 months of concurrent therapy, consider alternatives.

Concurrent use with insulin in type 2 diabetes mellitus

Adults ages 17 and older: Continue current insulin dosage while starting metformin at 500 mg P.O. once daily. If response inadequate, increase metformin dosage by 500 mg after approximately 1 week and then by 500 mg weekly until glycemic control is achieved. Maximum metformin dosage is 2,500 mg. Optimally, decrease insulin dosage 10% to 25% when fasting plasma glucose level is below 120 mg/dl. Individualize dosage adjustments based on glycemic response.

Dosage adjustment

• Elderly or debilitated patients

Contraindications

• Hypersensitivity to drug

• Acute or chronic metabolic acidosis (including diabetic ketoacidosis) with or without coma

• Underlying renal dysfunction

• Heart failure requiring drug therapy

Precautions

Use cautiously in:

• renal impairment, myocardial infarction, cerebrovascular accident, hypoxia, sepsis, pituitary deficiency or hyperthyroidism, dehydration, hypoxemia, chronic alcohol use

• elderly or debilitated patients

• pregnant or breastfeeding patients

• children (safety not established).

Administration

• Administer with a meal.

• Make sure patient swallows extended-release tablets whole without crushing or chewing.

• Don't administer extended-release tablets to children.

• Know that drug is given with diet therapy, sulfonylureas, or both.

Adverse reactions

GI: diarrhea, nausea, vomiting, abdominal bloating

Metabolic: lactic acidosis

Other: unpleasant metallic taste, decreased vitamin B12 level

Interactions

Drug-drug. Amiloride, calcium channel blockers, digoxin, morphine, procainamide, quinidine, ranitidine, triamterene, trimethoprim, vancomycin: altered response to metformin

Cimetidine, furosemide, nifedipine: increased metformin effects

Iodinated contrast media: increased risk of lactic acidosis

Drug-diagnostic tests. Urine ketones: false-positive results

Drug-herbs. Glucosamine: decreased glycemic control

Chromium, coenzyme Q10, fenugreek: additive hypoglycemic effects

Drug-behaviors. Alcohol use: increased metformin effects

Patient monitoring

• When switching from chlorpropamide, stay alert for hypoglycemia during first 2 weeks of metformin therapy; chlorpropamide may stay in body for prolonged time. Conversion from other standard oral hypoglycemics requires no transition period.

• Monitor blood glucose level closely. If it isn't controlled after 4 weeks at maximum dosage, oral sulfonylurea may be added.

• Monitor kidney and liver function tests, particularly in elderly patients.

• Assess hematologic parameters and vitamin B12 levels at start of therapy and periodically thereafter.

Watch for signs and symptoms of lactic acidosis. Stop drug if acidosis occurs. To aid differential diagnosis, check electrolyte, ketone, glucose, blood pH, lactate, and metformin blood levels.

• Periodically monitor glucose and glycosylated hemoglobin levels to evaluate drug efficacy.

Patient teaching

• Teach patient about diabetes and importance of proper diet, exercise, weight control, and blood glucose monitoring.

• Inform patient that drug may cause diarrhea, nausea, and upset stomach. Advise him to take it with meals to reduce these effects, and tell him that adverse effects often subside over time.

Teach patient to recognize and immediately report signs and symptoms of acidosis, such as weakness, fatigue, muscle pain, dyspnea, abdominal pain, dizziness, light-headedness, and slow or irregular heartbeat.

• Advise patient to report changes in health status (such as infection, persistent vomiting and diarrhea, or need for surgery). These may warrant dosage decrease or drug withdrawal.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.

Glucophage

(glo͞o′kō-fāj′)
A trademark for the drug metformin.

metformin

A biguanide antihyperglycaemic and antidiabetic used for type-2 diabetes, alone or with sulfonurea. Metformin sensitises cells to insulin, decreases serum glucose and insulin, decreases insulin resistance, increases glucose utilisation, decreases triglycerides, and reduces weight; in some patients, it suppresses appetite.

Adverse effects
GI tract complaints—e.g., diarrhoea, nausea, vomiting, bloating—occur in 30%.
 
Contraindications
Metabolic acidosis, liver disease; metformin has an equal and additive effect with troglitazone, which acts by increased peripheral glucose disposal.

Glucophage®

Metformin, see there.

Glucophage

A brand name for METFORMIN.
References in periodicals archive ?
The company's abbreviated new drug application (ANDA) for metformin hydrochloride extended release tablets in the 500 mg and 750 mg strengths is the generic equivalent for the corresponding strengths of the branded product Glucophage XR sold in the US by Bristol-Myers Squibb.
Until now, Glucophage was imported from Europe to the Middle East, but with the drug being manufactured locally, it reduces the lead time for products to reach the market, reducing supply shortfalls.
Glucophage is taken by diabetes patients, while other medications either out of stock or running low are Concor5 (for high blood pressure and heart conditions), Euthyrox (thyroid problems) and Lipitor (high cholesterol).
Ed made small changes in his diet and activities while traveling and was eventually able to manage his glucose levels with glucophage (Metformin[R]), diet, and activity.
One of the most prescribed medications in kids and adults with type 2 diabetes is metformin (Glucophage).
In fact, the Diabetes Prevention Program, a large clinical trial reported in 2002, showed that, for pre-diabetic adults, a lifestyle approach was twice as effective at preventing the development of diabetes as the drug metformin (Glucophage, Fortamet).
This new finding could lead to wider use of the drug - particularly in people with cancer and diseases linked to TSC deficiency like tuberous sclerosis and lymphangioleiomyomatosis (LAM).The study led by George Thomas, PhD, scientific director of UC's Metabolic Diseases Institute, are published in the Cell Metabolism.Metformin, marketed first by Bristol-Myers Squibb as Glucophage and now available in generic form and a number of combinations, is widely prescribed to people with type 2 diabetes and may be extended to the treatment of certain cancers.
But an older diabetes drug, metformin (Glucophage), has been shown to protect against cardiovascular death.
According to The National Diabetes Information Clearinghouse, or NDIC, (http://diabetes.niddk.nih.gov): The DPP was a major multicenter clinical research study aimed at discovering whether modest weight loss through dietary changes and increased physical activity or treatment with the oral diabetes drug metformin (Glucophage) could prevent or delay the onset of type 2 diabetes in study participants who, at the beginning of the DPP, were all overweight and pre-diabetic.
However, metformin, trade name Glucophage, seems to counteract sitagliptin's adverse effect.